What's Happening?
Arrowhead Pharmaceuticals has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending the approval of REDEMPLO (plozasiran) for reducing triglyceride levels in adults with familial
chylomicronemia syndrome (FCS). This recommendation is based on the successful results of the Phase 3 PALISADE study, which demonstrated a median reduction of 80% in triglyceride levels among patients treated with REDEMPLO. The drug, which utilizes Arrowhead's Targeted RNAi Molecule (TRiM) platform, is designed to silence the mRNA encoding apolipoprotein C-III, a key regulator of triglyceride metabolism. If approved, REDEMPLO would be the first siRNA medicine authorized in the EU for both genetically confirmed and clinically diagnosed FCS patients.
Why It's Important?
The positive CHMP opinion is a significant milestone for Arrowhead Pharmaceuticals, potentially expanding treatment options for FCS, a rare and severe condition characterized by extremely high triglyceride levels and a high risk of acute pancreatitis. Current treatments for FCS are limited, and REDEMPLO's approval could provide a new therapeutic option for patients who do not have genetic confirmation of the condition. This development underscores the potential of RNA interference therapies in addressing unmet medical needs and could enhance Arrowhead's market position in the EU, following approvals in the U.S., Canada, and China.
What's Next?
The European Commission is expected to make a decision on the marketing authorization of REDEMPLO in the second quarter of 2026. If approved, Arrowhead will work with regulators and the healthcare community to facilitate access to this treatment across Europe. The company is also pursuing additional regulatory approvals globally and is conducting further studies to explore the drug's efficacy in other conditions related to hypertriglyceridemia.
